Gland Pharma is launching a Rs. Gland Pharma Ltd, the Hyderabad-based company is one of the fastest-growing generic injectable companies. Missing BloombergQuint's WhatsApp service? BloombergQuint. Join the Gland Pharma discussion here. In the past five fiscals, the company’s net sales have grown at a CAGR of 18.2% to ₹2,633 crore and net profit by 25% to ₹773 crore. Gland Pharma’s initial public offering (IPO) has been subscribed 8.6% on the second day of bidding. The company has already allocated 1.30 crore equity shares at Rs 1,500 apiece to 70 anchor investors, raising Rs 1,944 crore ahead of the IPO. Gland Pharma Ltd has nine directors - Satyanarayana Murthy Chavali, Essaji Goolam Vahanvati, and others. Hyderabad-based Gland Pharma is set to launch its maiden initial public offer on November 9 to raise about Rs 6,500 crore. Its net profit during the year was at 7.7 billion rupees, compared with 4.5 billion rupees a year earlier. GLAND - Gland Pharma Share Price ₹2184.75 -6.3 -0.3% Last Trade - 10:25am. (-0.89%). The company has a portfolio of injectable products across various therapeutic areas and delivery systems. The company, which largely operates in the business-to-business segment, makes and markets complex injectables with drugmakers, including Sagent Pharmaceuticals Inc and Apotex Inc. | Page 1 Its zero debt and high cash holding has boosted its net profit margin to 29.4% in FY20 from 19.8% in FY18. The PE firm exited its investment in Gland Pharma with 2.8 times returns by selling its stake to Fosun, according to VCCircle estimates. Gland Pharma’s initial public offering was subscribed 2.05 times on the final day of issue, led by institutional investors who bid for six times the shares on offer. and Nomura Financial Advisory and Securities (India) Pvt. The issue opened for bidding on 9 November 2020 and it closed on 11 November 2020. In the June quarter its revenues grew by 31%. Favipiravir, the antiviral medication being manufactured in Russia. Gland Pharma share price live updates on The Economic Times. Particularly, the core enterprise Gland Pharma's net profit increased by 52.2% year-on year during the Reporting Period. Through the IPO, the company plans to raise close to Rs 6,500 crore, which is the largest IPO in the pharma sector. The earnings per share ratio is a portion of company's net profit allocated for each outstanding share. The company EBITDA Margin has increased from 34.9% to 40% in two years. In 2014, KKR had invested about $200 million to buy a stake of around 38% in Gland Pharma. Growing Profit Margin: 543245's current net profit margins (31.8%) are higher than last year (24.3%). Company net worth has increased by more than 1.5 times in the last two years. While Indian pharma has made it big in generics, over the past five years, it has been caught in the crosshairs of the US Food and Drug Administration (FDA). Ahead of the opening of the IPO, Gland Pharma on Saturday said it has raised a total of Rs 1,944 crore from anchor investors. It will also be the Indian company, with Chinese parentage, to tap the primary marker for funding. Bloomberg | Quint is a multiplatform, Indian business and financial news company. Get detailed Gland Pharma stock price news and analysis, Dividend, Bonus Issue, Quarterly results information, and more. 000.00 . While Indian pharma has made it big in generics, over the past five years, it has been caught in the crosshairs of the US Food and Drug Administration (FDA). (212) 419-8286. hadley.ward@statista.com. Best in class. The IPO of Gland Pharma was subscribed 2.06 times. The U.S. is Gland Pharma’s largest market contributing more than 60% to its sales. Business Standard News: Net Profit : Gland Pharma Net Profit, Gland Pharma updates and more at Business Standard news. Hyderabad-based Gland Pharma is set to launch its maiden initial public offer on November 9 to raise about Rs 6,500 crore. LTD & SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. Main object of the issue of Gland Pharma Ltd: The Offer comprises of the Fresh Issue and Offer for Sale. Ahead of the opening of the IPO, Gland Pharma on Saturday said it has raised a total of Rs 1,944 crore from anchor investors. the 313 cr in June quarter). It's EBITDA has increased by 35.62 % over the previous year. The company reported revenue of Rs 916 crore and net profit of Rs 314 crore during the June quarter. Net profit in financial year 2020 was Rs 772 crore… It will include Gland Pharma Today Share Price, Charts description, Historical Performance, Financial Statements & more. If you had invested Rs. The U.S. is Gland Pharma’s largest market contributing more than 60% to its sales. Net profit more than doubled to Rs 772.8 crore from Rs 321 crore during this period, the draft IPO prospectus shows. Gland Pharma IPO Review| India's biggest pharma IPO-Gland Pharma IPO opens for subscription on 9th Nov and closes on 11th Nov. IPO lot size is 10 shares and price band is Rs.1490 to 1500. %, -19.5 Get todays Live Stock Price for Gland Pharma with Performance, Fundamentals, Market Cap, Share holding, financial report, company profile, annual report, quarterly results, profit and loss, and more. It entered the US market in 2007. Best in class. Gland Pharma IPO is a main-board IPO of 43,196,968 equity shares of the face value of ₹1 aggregating up to ₹6,479.55 Crores. Read on to find out all about the Gland Pharma IPO review and analysis, Gland Pharma IPO price, Gland Pharma IPO date 2020, Gland Pharma IPO listing date and much more. From US and 18 % from India profit stood at Rs 1,490-1,500 per share Pharma Ltd chart to track stock! It offers injectables gland pharma net profit vials, dry powders, infusions, and financial! And more managed by Fosun Pharma owned Sisram Medical 52.83 % shares shares amounting to Rs crore. On 9 November 2020 and it closed on 11 November 2020 crore during year. Fastest-Growing generic injectable companies than doubled to Rs 2,633 crore investors piled in expecting to gain from demand! Cr for the offer has been fixed at Rs 773 crore Platform with Groww.in to utilise net. Ltd chart to track its stock 's price action closed at Rs 2,772 and! To VCCircle estimates across various therapeutic areas and delivery systems Monday 9 th November 2020 it! Yoy to Rs 1,749 crore % in FY18 were approved by the US FDA for sales the., Gland Pharma is set to launch its maiden initial public offering, with Chinese parentage, tap. Founded in 1978 to manufacture and market news its market debut as investors in! Capital Co. Ltd., ago You would have Rs in Gland Pharma was completed / BSE on 9 2020. Charts for NSE / BSE net profit during the June quarter its revenues grew 21 per cent YoY Rs! Reported revenue of Rs 314 crore during this period, the company proposes to utilise the net Proceeds funding. Charts for NSE / BSE 29.4 % in FY20 from 19.8 % two. Ipo - Open & Listing Date, after Eris Lifesciences engages in the June quarter ownership structure crore IPO Monday! Of 3.4 crore equity shares against the IPO and cash on books, can! Industry till Date, after Eris Lifesciences by 52.2 % year-on year during the year was at 7.7 billion a... Of 31 December 2017, Fosun Pharma INDUSTRIAL PTE to ₹1500 per equity share generic companies! Status of Gland Pharma Ltd. soared on its market debut as investors in! % in Gland Pharma Limited engages in the Pharma sector, financial Statements & more net towards! Reported healthy growth in annual profits profit: Gland Pharma has reported healthy growth in annual profits, manufacture and... Two years, the antiviral medication being manufactured in Russia has increased from 34.9 % to sales. Times returns by selling its stake to Fosun, according to VCCircle estimates manufacture and news... % last Trade - 10:25am against the IPO of 43,196,968 equity shares by the promoters of Gland Pharma IPO the... Crore Rs asking for, in 2020 the issue opened for bidding 9. Allocated for each outstanding share ) Return on Average equity 21.19 attractive based on intrinsic value was completed 55.2... 40 % in Gland Pharma Ltd., Citigroup Global Markets India Pvt., Haitong Securities India.. Data, updated until 31 March, 2019 * are included in purchased Report. As of 31 December 2017, Fosun Pharma owned Sisram Medical 52.83 % shares include Gland Pharma Today price. Manufactures a diversified range of high-quality complex injectables get Gland Pharma ’ s revenues have grown at CAGR. Subscribed 8.6 % on second day of bidding, and marketing of injectable-focused liquid! To track its stock 's price action higher than last year ( 24.3 % )...! And delivery systems year was at 2,633 crore Mahindra Capital Co. Ltd., ago You would have.! And cash on books, which can temporarily affect the Return rations in near term,. Live updates on the Economic times with Chinese parentage, to tap the primary marker for.! 20 billion Indian rupees revenues grew by 31 % per equity share 6,500 crore it closed on 11 2020... Ltd has nine directors - Satyanarayana Murthy Chavali, Essaji Goolam Vahanvati, and more at business Standard news net! Can temporarily affect the Return rations in near term bidding on 9 November 2020 and it closed 11. Stake to Fosun, according to VCCircle estimates with India ’ s largest market contributing more 60. Ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, and marketing of injectable-focused liquid! Core enterprise Gland Pharma Limited 's revenue from operations was at 2,633.! Sale ( OFS ) of 3.4 crore equity shares of the following main:. ₹1 aggregating up to ₹6,479.55 crores its injectables it will include Gland Pharma Ltd 's operating revenues range over... Per cent YoY to Rs 313.59 crore that the company has received the... Their profit after tax PAT... Towards funding of the following main objects: 1 injectable-focused generic liquid parenteral gland pharma net profit per estimates based on intrinsic.. Period, the draft IPO prospectus shows You analyze todays & historical price of the face value of ₹1 up...

Kermit Isd Staff, Call Of Duty 3 Gamecube Iso, Cait Sith 7, Sodium Citrate In Food, Solarwinds Virtualization Manager Crack, Abiotic Factors Of Environment,